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Interactionwith prohibitin (PHB) is required for full activation of CRAF kinase, the centralmember of the highly
conserved RAS-CRAF-MAPK pathway. In this issue ofChemistry & Biology, Polier et al. show that the natural
anti-tumor compounds rocaglamides target the CRAF-PHB interaction to disrupt theMAPK pathway leading
to proliferation block in human leukemic cells.Prohibitin is an evolutionarily conserved,
ubiquitously expressed, pleiotropic pro-
tein that is localized to various sub cellular
compartments (Mishra et al., 2010). Pro-
hibitin is involved in regulating the activa-
tion of CRAF kinase, which binds to RAS
in a GTP-dependent manner and triggers
the MAPK pathway (Rajalingam and Ru-
del, 2005; Rajalingam et al., 2005). Upon
activation, RAS oncogenes trigger
different pathways, including the RAF-
MEK-ERK pathway that has gained enor-
mous attention given that it controls
various cellular processes including pro-
liferation, survival, differentiation, migra-
tion, and metastases (Downward, 2003).
RAF kinases comprise a family of three
isoforms (ARAF, BRAF, and CRAF) and
CRAF was the first RAS effector to be
identified (Rajalingam et al., 2007). RAF
kinases consist of three conserved
regions (CR) 1–3, where CR3 constitutes
the kinase domain. RAS binds to the Ras
Binding Domain of RAF kinases and
recruit them to plasma membrane where
a series of phosphorylation and dephos-
phorylation events happen leading to
RAF kinases activation. RAF kinases
subsequently phosphorylate MEK1/2,
which in turn phosphorylates and acti-
vates ERK1/2 thus forming the three-tier
MAPK cascade (Rajalingam et al., 2007).
This pathway is activated either directly
or indirectly in a large percentage of
human tumors, and several chemothera-
peutic drugs have been developed to
target the kinases downstream of RAS,
with RAF inhibitors yielding significant
clinical success. While most of the small
molecule kinase inhibitors target the cata-
lytic domain (ATP competitive or non-ATPcompetitive inhibitors) relatively few of
them target the protein-protein interac-
tions driving the activation. In this issue
of Chemistry & Biology, Polier et al.
(2012) report rocaglamides as novel
CRAF kinase inhibitors that specifically
target the CRAF-prohibitin interaction in
tumor cells.
Prohibitin is the flagship member of the
stomatin/prohibitin/flotillin/HflK/C (SPFH)
domain [also known as the prohibitin
(PHB) domain] family of membrane
proteins primarily characterized by the
presence of the N-terminal hydrophobic
domain. Prohibitin 1 (PHB1) exists in
a complex with Prohibitin 2 (PHB2, also
called BAP37/prohibitone), forming stable
heteromers. Prohibitins form large ring
like assemblies in the mitochondrial inner
membrane contributing to mitochondrial
biogenesis. In the nucleus, prohibitins
have been shown to regulate the activity
of p53, Rb and E2Fs regulating apoptosis
(Mishra et al., 2010). Further, members of
SPFH family including prohibitins are
often found in the lipid raft microdomains
of various cellular membranes. Apart from
the hydrophobic domain at the N
terminus, PHB1 has also been shown to
be palmitoylated (at Cys69), phosphory-
lated (at Ser252, Ser254, Ser265, Thr258
and Tyr114, Tyr249 and Tyr259) and O-
GlcNac modified (at Ser121 and Thr258)
(Mishra et al., 2010). The physiological
relevance of these modifications and their
cross talk in regulating prohibitin func-
tion(s) has been under intense investiga-
tion. Recent studies revealed that palmi-
toylation of PHB1 leads to localization of
PHB1 to the plasma membrane and inter-
action with Eps 15 homology domainChemistry & Biology 19, September 21, 2012 ªprotein 2 (EHD2) (Mishra et al., 2010).
Prohibitin is also recognized as a vascu-
lar marker for white adipose tissue.
Several viral coat proteins and Vi polysac-
charide from Salmonella target the
plasma membrane associated prohibitins
possibly influencing the downstream
signaling and immune response bymodu-
lating ERK1/2 signaling (Sharma and
Qadri, 2004). Prohibitins are found to
be associated with IgM receptors in
B-lymphocytes and have recently been
detected to be surface-exposed in
activated T cells (Yurugi et al., 2012).
Interestingly, blocking of surface exposed
prohibitins with antibodies in T cells leads
to reduced ERK1/2 activation, suggesting
a crucial role for plasmamembrane-asso-
ciated PHB in the modulation of immune
responses (Yurugi et al., 2012).
PHB1 directly interacts with CRAF and
is required for the displacement of 14-3-
3 from CRAF from an internal binding
site (located at Ser259), which is crucial
for RAS-CRAF interaction at the plasma
membrane (Figure 1). Loss of PHB1 pre-
vented the localization of CRAF to
membranes leading to an increase in
Ser259 phosphorylation and 14-3-3 inter-
action in the cytosol, thus, inactivating
CRAF kinase (Rajalingam et al., 2005).
Interaction with CRAF is primarily medi-
ated through the C-terminal 30 amino
acid residues in PHB1 and a mutant of
prohibitin lacking these residues failed to
revert CRAF activation in PHB1-depleted
cells (Rajalingam et al., 2005). Consis-
tently, plasma membrane associated
PHB1 was recently shown to be positively
correlated to clinical stages of cervical
cancer (Chiu et al., 2012). Here,2012 Elsevier Ltd All rights reserved 1077
Figure 1. Rocaglamides Disrupt PHB-CRAF Interaction Leading to
Inactivation of CRAF Kinase
Activation of RAS recruits CRAF to the plasma membrane where prohibitin is
required for the displacement of 14-3-3 from Ser259 to facilitate CRAF activa-
tion. PP2A dephosphorylates Ser259, leading to phosphorylation at Ser 338,
and dephosphorylates Tyr341, by activating kinases, leading to full activation
of CRAF kinase. Rocaglamides directly disrupt PHB1-CRAF interaction, thus,
rendering CRAF kinase inactive.
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Thr258 (mediated by Akt1)
enhances CRAF association
leading to hyperactivation of
ERK1/2 kinases thus pro-
moting metastases of cer-
vical cancer cells to lymph
nodes (Chiu et al., 2012).
Further, increased expres-
sion of prohibitin at the
plasma membrane contrib-
utes to paclitaxel resistance
in NSCLC cells (Patel et al.,
2010). Taken together,
emerging evidence strongly
supports for a crucial role of
plasma membrane associ-
ated prohibitins which may
be therapeutically exploited.
Rocaglamides are a group
of phytochemicals derived
from the medicinal plants
belonging to genus Aglaia
(Meliaceae) and previous
studies have shown that these
compounds trigger apoptosis
at nanomolar concentrations
in leukemic cells by inhibitionof MAPK pathway and protein synthesis
(Zhu et al., 2007). In the newestwork, Polier
et al. (2012) used an affinity chromatog-
raphy approach to identify the cellular
targets of rocaglamide A (Roc-A) in
leukemic cells. Mass spectrometric anal-
ysis of co-precipitated proteins revealed
that Roc-A targeted prohibitins. Interest-
ingly, the authors detect that binding of
Roc-A to prohibitins prevents CRAF-PHB
interactions both in vitro and in vivo thus
leading to impaired ERK1/2 activation in
these cells (Figure 1). As expected, Roc-A
treatment did not influence the activation
of BRAF or ARAF. Further, the authors
present evidence that Roc-A treatment
neither influence the morphology of mito-
chondria nor induce apoptosis in HeLa
cells. These effects were mirrored by
depletion of prohibitins with siRNAs, and
the defects in MAPK pathway were
rescued by treatment of cells with PMA,
a strong activator of ERK1/2 kinases
through PKCs. Consistent with previous
observations (Sievers et al., 2010), loss of
PHB1 with siRNAs or Roc-A treatment
leads to cell cycle arrest at theG1/ S phase
via downregulation of cell cycle regulatory1078 Chemistry & Biology 19, September 21,proteins cyclin D3, CDK4, CDK6, and
Cdc25A (Polier et al., 2012).
Taken together, these data reveal roca-
glamides as novel CRAF specific inhibi-
tors which target a protein-protein inter-
action rather than the catalytic kinase
domain. The structures of the catalytic
domains of various kinases are highly
similar and many of the ‘‘specific’’ inhibi-
tors target multiple kinases rather than
the intended targets. Furthermore, tumor
cells quickly acquire resistance to
kinase inhibitors and therefore novel ther-
apeutic drugs targeting regions outside
the kinase domain are much needed.
Rocaglamides are promising drugs of
this kind and treatment with these
compounds has already been shown to
inhibit tumor growth in vivo. Whether
Roc-A exhibits similar effects in solid
tumors, especially the ones with muta-
tions in RAS and other oncogenes needs
to be pursued. Since the novel class
of BRAFV600E inhibitors paradoxically
trigger the MAPK pathway in melanomas
carrying mutated RAS through CRAF,
combining Roc-A with BRAF inhibitors
may enhance the efficiency of these2012 ª2012 Elsevier Ltd All rights reservedotherwise successful anti-
melanoma drugs. As prohibi-
tin is pleiotropic, rocagla-
mides will also serve as
a valuable tool to decipher
the PHB-RAF interactions in
regulating various cellular
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